Accordingly, our recently completed clinical trials demonstrated that selective enhancement of CTL attraction to tumor tissues can be achieved not only by intratumoral (21, 22) but also systemic application (18, 23) of the CKM. This evidence concerns the gene CKM and neoplasm.